Precision Biotherapeutics

18.11.2025

Precision Biotherapeutics

Context

In November 2025, advancements in genomics, CRISPR technology, and personalised medicine positioned India to develop next-generation precision biotherapeutics aimed at treating genetic, metabolic, and cancer-related disorders.

About Precision Biotherapeutics

What are Precision Biotherapeutics?

Precision biotherapeutics refers to a new generation of medical treatments—drugs, biologics, or gene therapies—customised according to an individual’s genetic, molecular, or cellular profile rather than using uniform treatment methods.

Key Features

• Customised therapies based on genomic and molecular profiling.
• Utilises CRISPR gene editing, mRNA-based therapeutics, monoclonal antibodies, and CAR-T therapy.
• Focuses on correcting underlying causes instead of only alleviating symptoms.
• Employs AI and big-data analytics for accurate drug design and predictive response analysis.

How Precision Biotherapeutics Work

1. Genomic Profiling: DNA or RNA sequencing identifies key mutations or biomarkers responsible for disease.
2. Molecular Targeting: Faulty genes or proteins are pinpointed through advanced molecular biology techniques.
3. Therapeutic Design: Gene editing or biologic tools are used to repair, block, or modify malfunctioning genes or pathways.
4. Personalised Delivery: AI-driven dosage and delivery optimisation ensures safety and effectiveness.
5. Feedback Mechanism: Continuous clinical and genomic monitoring refines and adapts therapy in real time.

Applications

• Cancer: Tailored immunotherapies and monoclonal antibodies improve efficacy without major side effects.
• Genetic Disorders: CRISPR and gene-replacement technologies offer near-curative solutions for inherited diseases like thalassemia and SMA.
• Cardiometabolic Conditions: RNA-based drugs personalise therapy for diabetes, cholesterol, and hypertension.
• Rare Diseases: Gene and enzyme replacement therapies expand treatment access for ultra-rare disorders.
• Infectious Diseases: mRNA vaccine technology enables rapid response to emerging viral variants.

Challenges

• Regulatory Uncertainty: No unified regulatory structure for gene, cell, and RNA-based therapies delays approval and research.
• High Development Cost: Complex production processes make treatments expensive and inaccessible to many patients.
• Limited Manufacturing Infrastructure: Inadequate GMP-certified biomanufacturing facilities create dependence on imports.
• Data Privacy Risks: Genomic data faces potential misuse in the absence of a robust privacy framework.
• Restricted Clinical Trial Ecosystem: Few advanced trials hinder scalability and innovation in precision therapies.

Way Forward

• Dedicated Regulatory Pathway: Establish a specialised CDSCO-led framework for evaluating gene, cell, and mRNA therapeutics.
• Genomic Data Governance: Formulate a genomic data protection law and ethical biobanking standards.
• Biomanufacturing Expansion: Promote public-private partnerships to develop indigenous high-quality production hubs.
• Integration with Public Health: Incorporate precision therapy coverage under Ayushman Bharat to enhance affordability and accessibility.
• Bioethics Oversight: Create a National Bioethics Commission to guide ethical compliance, patient consent, and safety norms.

Conclusion

Precision biotherapeutics represent a transformative shift toward individualised healthcare, grounded in genetics and data-driven insights. For India, the approach offers both improved health outcomes and global leadership prospects in affordable biotechnology. A well-regulated, ethically guided, and investment-supported framework can help democratise these advanced therapies for all citizens.